Indexat a

Enllaç extern

Llicència i ús

Citacions

Altmetrics

Anàlisi d'autories institucional

Esteve-Sánchez, YAutor o coautorHernández-Montoto, AAutor o coautorMarcos, MdAutor o coautorMartínez-Máñez, RAutor (correspondència)Aznar, EAutor (correspondència)

Compartir

SARS-CoV-2 N protein IgG antibody detection employing nanoporous anodized alumina: A rapid and selective alternative for identifying naturally infected individuals in populations vaccinated with spike protein (S)-based vaccines

Publicat a:Sensors And Actuators B-Chemical. 419 136378- - 2024-11-15 419(), DOI: 10.1016/j.snb.2024.136378

Autors: Esteve-Sanchez, Yoel; Hernandez-Montoto, Andy; Tormo-Mas, Maria Angeles; Peman, Javier; Calabuig, Eva; Gomez, Maria Dolores; Marcos, Maria Dolores; Martinez-Manez, Ramon; Aznar, Elena; Climent, Estela

Afiliacions

Resum

Methods to detect naturally infected individuals, especially during or after a pandemic, are valuable in populations with a high rate of vaccination. Having in mind that after the COVID-19 pandemic people has been vaccinated against the virus by Spike protein (S)-based vaccines, we present in this paper a novel nanosensor based on gated nanoporous anodic alumina (NAA) material to detect naturally infected individuals in populations with high rates of vaccination. The nanosensor developed is based on a protein-capped nanomaterial for the identification of IgG antibodies that can detect nucleocapsid protein (N) of SARS-CoV-2. The NAA material has been loaded with an indicator (Rhodamine B (RhB)) and the pores of the material have been blocked with SARS-CoV-2 nucleocapsid protein (N) attached to a specific aptamer. In presence of antibodies against this antigen, the pores are uncapped, triggering the dye release and a fluorescent signal as a result. The biosensor has been tested in vitro and simulated serum for IgG detection, proving a detection limit of 1 mu g/mL. Moreover, specificity assays with N proteins from other coronaviruses have proved the robustness and efficacy of this nanosensor. Finally, the system has been tested on samples from patients that contained SARS-CoV-2 antibodies, demonstrating its potential for the discrimination of individuals that have been vaccinated or infected by SARS-CoV-2 virus.

Paraules clau